*3.3. Negative E*ff*ect of Reduced NME1 Expression on RFS in Patients with Cisplatin-Based Adjuvant Chemotherapy and* β*-Catenin Overexpression*

Cisplatin-based adjuvant chemotherapy was not associated with RFS irrespective of histologic subtypes in univariate analysis. The effect of NME1 or β-catenin on RFS was further analyzed considering cisplatin-based adjuvant chemotherapy. The negative effect of reduced NME1 expression on RFS was worse in patients treated with (Figure 3A) cisplatin-based adjuvant chemotherapy than in those treated without (Figure 3B). Reduced NME1 expression was not associated with β-catenin overexpression in this study. However, it is known that there is a complex interplay between NME1 and β-catenin in a variety of cancers. Therefore, data were further stratified according to β-catenin overexpression. The negative effect of reduced NME1 expression on RFS was much greater in patients with overexpression of β-catenin (Figure 3C) than in those without (Figure 3D).

**Figure 3.** Effect of NME1 on recurrence-free survival, stratified by β-catenin expression and cisplatin-based adjuvant chemotherapy. To understand whether the effect of NME1 on RFS was confounded by β-catenin expression or cisplatin-based adjuvant chemotherapy, data were stratified by β-catenin overexpression (**A**,**B**) or cisplatin-based adjuvant chemotherapy (**C**,**D**) and then the survival curves were compared according to NME1. The survival was compared using the log-rank test in 425 non-small cell lung cancers (NSCLCs).
